Suchergebnisse - David Russell‐Jones

Treffer weiter einschränken
  1. 1
    Recent advances in incretin‐based therapies

    Recent advances in incretin‐based therapies von David Russell‐Jones, Stephen Gough

    Veröffentlicht 2012
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Growth hormone and sport: abuse, potential benefits, and difficulties in detection.

    Growth hormone and sport: abuse, potential benefits, and difficulties in detection. von Marie Louise Healy, David Russell‐Jones

    Veröffentlicht 1997
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Identification of barriers to insulin therapy and approaches to overcoming them

    Identification of barriers to insulin therapy and approaches to overcoming them von David Russell‐Jones, Frans Pouwer, Kamlesh Khunti

    Veröffentlicht 2017
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men

    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men von M. Denise Robertson, David Russell‐Jones, A. Margot Umpleby, Derk‐Jan Dijk

    Veröffentlicht 2012
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Insulin X10 revisited: a super-mitogenic insulin analogue

    Insulin X10 revisited: a super-mitogenic insulin analogue von Bent Hansen, Peter Kurtzhals, Astrid B. Jensen, A. Dejgaard, David Russell‐Jones

    Veröffentlicht 2011
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials

    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials von David Russell‐Jones, M.‐A. Gall, M. Niemeyer, M. Diamant, Stefano Del Prato

    Veröffentlicht 2015
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Miscoding, misclassification and misdiagnosis of diabetes in primary care

    Miscoding, misclassification and misdiagnosis of diabetes in primary care von Simon de Lusignan, Norah Hassan Sadek, Henrietta Mulnier, Aumran Tahir, David Russell‐Jones, Kamlesh Khunti

    Veröffentlicht 2011
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp von S. V. M. Hordern, Jonelle E. Wright, A. Margot Umpleby, Fariba Shojaee‐Moradie, J. Amiss, David Russell‐Jones

    Veröffentlicht 2005
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes

    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes von Marie Louise Healy, James Gibney, David Russell‐Jones, Claire Pentecost, P Croos, P H Sönksen, A. Margot Umpleby

    Veröffentlicht 2003
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial von David Russell‐Jones, Allan Vaag, O. Schmitz, Bipin Sethi, Nebojša Lalić, Slobodan Antić, Marija Zdravković, Gabriela Martinez Ravn, Rafael Simó

    Veröffentlicht 2009
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial von Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Veröffentlicht 2018
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes

    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes von Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock

    Veröffentlicht 2022
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome

    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome von M. Denise Robertson, John W. Wright, Emmanuelle Loizon, Cyrille Debard, Hubert Vidal, Fariba Shojaee‐Moradie, David Russell‐Jones, A. Margot Umpleby

    Veröffentlicht 2012
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) von David Russell‐Jones, Robert Cuddihy, M Hanefeld, Ajay Kumar, José Gerardo González‐González, Melanie Chan, Anne M. Wolka, Marilyn K. Boardman

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes

    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes von Helen Simpson, Nicola Jackson, Fariba Shojaee‐Moradie, R. H. Jones, David Russell‐Jones, Peter H. Sönksen, David B. Dunger, A. Margot Umpleby

    Veröffentlicht 2004
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK

    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK von Harry Knights, Nikhil Mayor, Kristina Millar, Matthew Cox, Evgeniya Bunova, Morgan Hughes, Jack W. Baker, Sanju Mathew, David Russell‐Jones, Aleksandra Kotwica

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Tr... von Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell‐Jones, J. B. Larsen, Søren C. Tamer, Stephen C. Bain

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial

    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label,... von David Russell‐Jones, Tetsuya Babazono, Roman Cailleteau, Susanne Engberg, Concetta Irace, Maiken Ina Siegismund Kjaersgaard, Chantal Mathieu, Julio Rosenstock, Vincent Woo, David C. Klonoff

    Veröffentlicht 2023
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes

    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes von Philip Home, Paul B. Bartley, David Russell‐Jones, H Hanaire-Broutin, Jan‐Evert Heeg, Pascale Abrams, Mona Landin–Olsson, Birgitte Hylleberg, Hanne Lang, Eberhard Draeger

    Veröffentlicht 2004
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Efficacy of increased resistant starch consumption in human type 2 diabetes

    Efficacy of increased resistant starch consumption in human type 2 diabetes von Caroline L. Bodinham, Lee Smith, E. Louise Thomas, Jimmy D. Bell, Jonathan R. Swann, Adele Costabile, David Russell‐Jones, A. Margot Umpleby, M. Denise Robertson

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: